MYCN

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Retrieved on: 
Monday, March 25, 2024
Research, Cancer Research UK, Biochemistry, Drug design, Partnership, Physician, Patient, SAN, MYCN, University, Cancer, Inflammation, TPD, Doctor of Philosophy, Therapy, Molecular biology, ALK, Pediatrics

SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that it is part of a diverse research team of international experts selected as awardees in this year’s Cancer Grand Challenges competition. The team includes scientists, physicians and patient advocacy groups from 10 institutions in the United States, the United Kingdom, France, Germany and Austria and will be led by Yael Mossé, M.D., Professor of Pediatrics and Patricia Brophy Endowed Chair in Neuroblastoma Research at the Children’s Hospital of Philadelphia, and Martin Eilers, Ph.D., Professor of Biochemistry and Molecular Biology at the University of Würzburg, Germany.

Key Points: 
  • The project entitled “Knocking Out Oncogenic Drivers and Curing Childhood Cancers” (KOODAC) has the goal of developing orally bioavailable targeted protein degraders that have the potential to dramatically improve cure rates for children affected by solid tumors.
  • "Team KOODAC brings together an interdisciplinary, international team of scientific experts, all sharing the vision of developing safe and effective drugs against previously undruggable childhood cancers," said Dr. Mossé.
  • This year, five teams were selected to receive funding of up to £20 million (approximately $25 million) over a period of five years.
  • The funds, which will support only the academic groups involved in the project, will be managed by Team KOODAC.

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Retrieved on: 
Monday, February 5, 2024
MYCN, Toxicity, SAN, Neoplasm, NCI, Glomus tumor, SN-38, DNA, Cmax, SLFN11, Clinical trial, Gene, Biomarker, Cell division, Patient, Safety, Irinotecan, Pros, Central nervous system, MYC, PEGylation, CNS, Phase, Medulloblastoma, TTY, Cancer, Bangladesh Technical Education Board, Ependymoma, Pharmaceutical industry

National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.

Key Points: 
  • National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
  • High levels of MYC drive oncogenesis in many cancers and induce DNA changes leading to the formation of “topoisome complexes”.
  • The NCI trial will assess whether PLX038 is safe and efficacious in primary CNS tumors driven by MYC or MYCN amplifications.
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma

Retrieved on: 
Monday, April 3, 2023
Army, Neoplasm, Band of Parents, Science, Discovery, MD, Patient, Disease, Children's Hospital of Philadelphia, ALK, Neuroblastoma, Emory University, St. Baldrick's Foundation, Alex's Lemonade Stand Foundation, Pediatrics, Consortium, CHOP, Wipe Out Kids' Cancer, Crizotinib, Research, Lung cancer, Pfizer, MYCN, Anaplastic lymphoma kinase, DOI, Hospital, FDA, NCI, Alvin J. Siteman Cancer Center, Safety, New Approach to Appraisal, Emory University School of Medicine, Winship Cancer Institute, Lipid, Development of the human body, COG, Children's Oncology Group, Weight gain, National Cancer Institute, International Society, Cancer, Adolescence, Band, Ronan (song), Clinical trial, Abdomen, Pharmaceutical industry, Medical imaging, Child, Nature Medicine, Parent

PHILADELPHIA, April 3, 2023 /PRNewswire/ -- In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma. The findings, published today in Nature Medicine, have led to a major amendment in a phase 3 Children's Oncology Group (COG) clinical trial, which has incorporated lorlatinib for newly diagnosed ALK-driven high-risk neuroblastoma, as well as a planned amendment to the European phase 3 trial in collaboration with the International Society of Paediatric Oncology European Neuroblastoma (SIOPEN).

Key Points: 
  • The difficulties we experienced in targeting ALK with crizotinib in neuroblastoma motivated us to find a more potent ALK inhibitor.
  • In the phase 1 NANT trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in pediatric, adolescent, and adult patients with relapsed/refractory ALK-driven neuroblastoma.
  • The researchers noted that younger patients treated with lorlatinib alone – particularly those with amplification of an oncogene called MYCN – had fewer responses compared to older patients.
  • "Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase I trial results," Nature Medicine, April 3, 2023, DOI: 10.1038/s41591-023-02297-5

SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

Retrieved on: 
Tuesday, August 9, 2022
Acute myeloid leukemia, Immortalised cell line, Survival, WT1, MYCN, Gene, BRCA1, GLOBE, Senior, NEW, Percentage, Drug, SEC, TP53, Annual report, AML, CDK9, Patient, NCI, Company, COVID-19, Acceleration, Therapy, Drug development, GPS, NASDAQ, Squamous cell carcinoma, RB1, Memorial Sloan Kettering Cancer Center, Ovarian cancer, MD, SLS, Adult, Terminology, Pharmaceutical industry, Vaccine, Greater China

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH009, in solid cancer and acute myeloid leukemia (AML) cell lines. The data shows that GFH009 demonstrated significant anti-tumor effects in all four selected cell lines. In three out of the four cell lines, GFH009 inhibited cancer cell growth by 90 to 100 percent.

Key Points: 
  • - In Three of the Four Cell Lines, GFH009 Inhibited Cancer Growth by 90 to 100 Percent -
    NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc .
  • (NASDAQ: SLS) (SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH009, in solid cancer and acute myeloid leukemia (AML) cell lines.
  • In three out of the four cell lines, GFH009 inhibited cancer cell growth by 90 to 100 percent.
  • NCI-H209: a small cell lung cancer cell line characterized by the loss of function of two major tumor suppressor genes, RB1 and TP53.

Northwestern Mutual deepens its decade-long commitment to fighting childhood cancer with $2 million donation to Alex's Lemonade Stand Foundation

Retrieved on: 
Wednesday, July 27, 2022
Alex's Lemonade Stand Foundation, Biopsy, University, Education, MYCN, Foundation, NLTC, Survivor, Research, Neuroblastoma, FINRA, SIPC, Pediatrics, Cancer, FORTUNE, Medulloblastoma, Clinical trial, Leadership, ALSF, Edie Lambert, Life, Mutation, LLC, Investor, CHOP, Child, Pharmaceutical industry, Financial adviser, Northwestern Mutual

MILWAUKEE, July 27, 2022 /PRNewswire/ -- Marking the 10-year anniversary of its Childhood Cancer Program, Northwestern Mutual, through its Foundation, has committed $2 million to Alex's Lemonade Stand Foundation (ALSF) to support the organization's Crazy 8 Initiative. As the initiative's largest funder, Northwestern Mutual's investment will support research for innovative and rigorous approaches that address the most intractable issues in pediatric cancer research.

Key Points: 
  • MILWAUKEE, July 27, 2022 /PRNewswire/ -- Marking the 10-year anniversary of its Childhood Cancer Program, Northwestern Mutual, through its Foundation, has committed $2 million to Alex's Lemonade Stand Foundation (ALSF) to support the organization's Crazy 8 Initiative .
  • "For 10 years, we are honoredthat Northwestern Mutual continues to be a steadfast partner to us in its commitment to finding childhood cancer cures," saidLizScott, co-executive director of Alex's Lemonade Stand Foundation and Alex's mom.
  • The mission of the Northwestern Mutual Foundation is to improve the lives of children and families in need.
  • Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra "Alex" Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer.

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

Retrieved on: 
Monday, May 2, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, JT Group Limited, Volunteering, US, Company, Safety, Neuroblastoma, Research, Patient, MYCN, Prospectus, Euronext Paris, Therapy, Adult, SEC, Infection, Technology, Lists of diseases, Fed, Pharmaceutical industry, EU, Cmax, Science

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecule drug targeting Neuroblastoma and potentially other cancer types.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecule drug targeting Neuroblastoma and potentially other cancer types.
  • Following the announcement of the Phase 1 clinical trial of SACT-1 in January 2022, Aptorum is pleased to announce further data updates from the trial conducted by an independent clinical contract research organization.
  • The phase 1 clinical data also suggested that any QT interval after oral administration of SACT-1 at 150mg was well within clinically acceptable limits.
  • We are planning to meet with the US FDA for an end of Phase 1 meeting as soon as possible and are targeting for submission for a Phase 1b/2a clinical trial in neuroblastoma patients.

Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Risk, Cisplatin, Form 10-K, TMB, Therapy, PALO, Translational medicine, Forward-looking statement, PNCA, Clinical trial, MCL, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Mouse, MYC, CDK9, AACR, Uterus, American Association, PCNA, Cancer, Failure, Tissue, Poster, Ovarian cancer, Oncology nursing, Association, Securities Exchange Act of 1934, Securities Act of 1933, Nasdaq, COVID-19, GLOBE, 8-K, MCL1, Neutrophil, Drug Quality and Security Act, ASH, MYCN, Blood, Patient, Toxicity, Pharmaceutical industry, Vaccine, Medical imaging, Neutropenia, Bayer

PALO ALTO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical and preliminary clinical data on VIP152, the Company’s PTEFb/CDK9 inhibitor, in gynecologic cancer cell lines and in patients with gynecologic malignancies, respectively, at the 2022 American Association for Cancer Research (AACR) Annual Meeting, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.

Key Points: 
  • Additionally, our preliminary VIP152 monotherapy clinical results as of March 2022 demonstrated an early signal in patients with gynecologic malignancies who have had multiple lines of prior therapy, continued Dr. Hamdy.
  • We are continuing to enroll patients in our Phase 1b expansion study across multiple tumor types including hematologic malignancies.
  • Antitumor efficacy was observed following a single 17.5 mg/kg dose of VIP152 monotherapy as demonstrated by tumor growth inhibition in the A2780 ovarian cancer xenograft model.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Retrieved on: 
Thursday, January 20, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, Euronext Paris, Survival, Research, Patient, Technology, Clinical trial, MYCN, SEC, Death, Infection, United, Lists of diseases, Therapy, Cancer, JT Group Limited, FDA, Prospectus, Pharmaceutical industry, Medical imaging, EU, Science, Neuroblastoma, IND, SACT-1, Neuroblastoma, Aptorum Group Limited, SACT-1, NEUROBLASTOMA, APTORUM GROUP LIMITED

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug Designation to SACT-1, a repurposed small molecule compound for the treatment of patients with Neuroblastoma.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug Designation to SACT-1, a repurposed small molecule compound for the treatment of patients with Neuroblastoma.
  • Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a phase 1b/2a clinical trial for SACT-1 to test the drug in neuroblastoma patients in 2022.
  • SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma.
  • This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

Retrieved on: 
Tuesday, January 18, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Euronext Paris, Research, IP, Patient, Technology, MYCN, SEC, US, Growth, Â, IND, Cancer, Infection, USPTO, Patent, Lists of diseases, Therapy, Megger Group Limited, United States patent law, Prospectus, Neuroblastoma, Pharmaceutical industry, Medical imaging, EU, Science

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorums SACT-1 repurposed drug for the treatment of various cancers including but not limited to neuroblastoma (US Patent 11,166,962 B2).

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorums SACT-1 repurposed drug for the treatment of various cancers including but not limited to neuroblastoma (US Patent 11,166,962 B2).
  • As IP protection is critically important for protecting our investment in developing repurposed drugs, the granted patent will further support our ongoing development effort of SACT-1 as a potentially effective treatment of neuroblastoma and other cancer types.
  • SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma.
  • This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

Retrieved on: 
Monday, January 10, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Aureus, Clinical trial, Vancomycin, Randomness, MRSA, SEC, Safety, Trial of the century, Nervous system, Single, US, JT Group Limited, Staphylococcus, Bacteria, Volunteering, Infection, Pharmacokinetics, Technology, Patient, World Health Organization, Brain, Neuroblastoma, Research, Adult, IND, ECG, Female, World, Methicillin, MAD, Staphylococcus aureus, Male, SAD, Lists of diseases, Euronext Paris, Vital signs, Prospectus, Therapy, Mortality, MYCN, Pharmaceutical industry, Science, EU, ALS-4, SACT-1, Aptorum Group Limited, ALS-4, SACT-1, APTORUM GROUP LIMITED

The safety data of the last SAD cohort (300mg) and MAD cohort (200mg twice a day for 14 days) are pending.

Key Points: 
  • The safety data of the last SAD cohort (300mg) and MAD cohort (200mg twice a day for 14 days) are pending.
  • SACT-1s first in-human clinical trial is a Phase 1, Open-label Randomized, Single Cross Over Bioavailability and Food Effect Study of SACT-1 in healthy adult volunteers.
  • Aptorum is pleased to announce the successful completion of the trial, during which no SAE were observed.
  • This milestone supports the focus of Aptorum Group to embark on the exciting Phase II clinical trials for ALS-4 and planned Phase Ib/2a clinical trials for SACT-1, subject to IND clearance.